Palm Beach Fertility Center Expands its Scope of Reproductive Services with INVOCell as INVO Bioscience Enters Florida

BOCA RATON, Fla. and MEDFORD, Mass., March 20, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcelltm, today announced that Palm Beach Fertility Center, with locations in Boca Raton and Lake Worth, Florida, is now offering the INVOcell Procedure as part of its compliment of reproductive treatments with the addition of INVOCell.

INVOcell has the ability to significantly transform the way in which doctors assist infertile patients to become pregnant in a simpler, more natural and cost-effective manner. INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman's body, in vivo. The simplistic INVO can be easily performed in an appropriately trained physician's office without the need for expensive overhead.

Dr. Mark Denker, M.D., founder of Palm Beach Fertility Center, commented, "We are pleased to add INVOCell to the available options to help our patients create the loving families that they so desire. We recognize that the cost of in-vitro fertilization (IVF) and other fertility treatments can add a great deal of stress to an already overwhelming process. INVOCell is a very cost-efficient process that can open the door to pregnancy to many couples that otherwise could not be served. We are excited with the possibilities going forward."

About Palm Beach Fertility Center
Founded in 1994 by Dr. Mark Denker, M.D., R.E.I., Palm Beach Fertility Center originated with the trailblazing idea of offering the best possible fertility treatments at the most affordable prices. Dr. Denker is Board Certified in Obstetrics and Gynecology with a specialization in Reproductive Endocrinology and Infertility. He is a long-standing member of the medical community and is widely considered to be a leader in the field of IVF, including advanced IVF procedures such as Preimplantation Genetic Diagnosis (PGD) and Intracytoplasmic Sperm Injection (ICSI). Dr. Denker and his highly trained team achieve impressive pregnancy successes and high IVF success rates and are renowned for their world class concierge care.   For more information, please visit http://www.palmbeachfertility.com

About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology ("ART"). The INVOcell is the first Intravaginal Culture ("IVC") system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization ("IVF") and Intrauterine Insemination ("IUI"). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/

Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504 
[email protected]

SOURCE INVO Bioscience, Inc.